REGENERON PHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss

The total revenue of RGO for the last quarter is 2.84 B CHF, and it's 1.88% lower compared to the previous quarter. The net income of Q1 24 is 651.33 M CHF.